Emgality (galcanezumab) vs Zavzpret (zavegepant)

Emgality (galcanezumab) vs Zavzpret (zavegepant)

Emgality (galcanezumab) is a once-monthly injectable monoclonal antibody designed to prevent migraines by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule involved in migraine attacks. Zavzpret (zavegepant), on the other hand, is a CGRP receptor antagonist taken orally or intranasally and is used for the acute treatment of migraine with or without aura in adults, providing relief during an ongoing migraine attack. When deciding between the two, a patient should consider whether they are seeking a preventive treatment (Emgality) or need a medication for immediate relief during migraine attacks (Zavzpret), and discuss their medical history and preferences with a healthcare provider.

Difference between Emgality and Zavzpret

Metric Emgality (galcanezumab) Zavzpret (zavegepant)
Generic name Galcanezumab Zavegepant
Indications Preventive treatment of migraine in adults Acute treatment of migraine with or without aura in adults
Mechanism of action Calcitonin gene-related peptide (CGRP) antagonist Calcitonin gene-related peptide (CGRP) receptor antagonist
Brand names Emgality Zavzpret
Administrative route Subcutaneous injection Oral
Side effects Injection site reactions, constipation, itching Nausea, dizziness, dry mouth
Contraindications Hypersensitivity to galcanezumab or any of the excipients Hypersensitivity to zavegepant or any of the excipients
Drug class Monoclonal antibody Small molecule CGRP receptor antagonist
Manufacturer Eli Lilly and Company Biohaven Pharmaceuticals

Efficacy

Emgality (Galcanezumab) for Migraine Prevention

Emgality (galcanezumab) is a calcitonin gene-related peptide (CGRP) antagonist designed for the prevention of migraine. Clinical trials have demonstrated its efficacy in reducing the frequency of migraine days in adults with episodic and chronic migraine. In these trials, patients treated with Emgality experienced a significant reduction in the number of monthly migraine days compared to placebo. The medication is administered once monthly via subcutaneous injection, which may be convenient for patients seeking a long-term preventive treatment option.

Zavzpret (Zavegepant) for Acute Migraine Treatment

Zavzpret (zavegepant) is a CGRP receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. Unlike Emgality, Zavzpret is used to treat migraine attacks as they occur, rather than for prevention. Clinical studies have shown that Zavzpret can provide relief from migraine pain and the most bothersome symptom identified by the patient when taken during a migraine attack. The drug has been shown to be effective in achieving pain freedom and relief from the most bothersome symptom at two hours post-dose compared to placebo.

Comparative Efficacy in Migraine Management

When comparing Emgality and Zavzpret, it is important to note that they serve different purposes in migraine management. Emgality is a preventive treatment, aiming to reduce the frequency of migraine episodes, while Zavzpret is intended for the immediate relief of migraine symptoms during an attack. Both medications target the CGRP pathway, which is believed to play a key role in the pathophysiology of migraine. The choice between these two medications would depend on a patient's specific needs, whether it is prevention or acute treatment.

Considerations for Use

While both Emgality and Zavzpret have shown efficacy in their respective roles, the decision to use either medication should be made in consultation with a healthcare provider. This decision will take into account the individual patient's migraine pattern, response to previous treatments, and any potential contraindications or side effects. It is also important for patients to be aware that while these medications can be effective, they may not work for everyone, and some may experience more benefit than others.

Regulatory Agency Approvals

Emgality
  • European Medical Agency (EMA), European Union
  • Food and Drug Administration (FDA), USA
  • Health Canada
  • Therapeutic Goods Administration (TGA), Australia
Zavzpret
  • Food and Drug Administration (FDA), USA

Access Emgality or Zavzpret today

If Emgality or Zavzpret are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email:

Contact us
LV Latvia 1